ХРОНИЧЕСКАЯ ОБСТРУКТИВНАЯ БОЛЕЗНЬ ЛЕГКИХ И МЕТАБОЛИЧЕСКИЙ СИНДРОМ: СОСТОЯНИЕ ПРОБЛЕМЫ (литературный обзор)

Ксения Алексеевна Вютрих; Лилия Владимировна Куколь; Владимир Вилорович Лазик

doi:10.21638/11701/spbu11.2017.102

Authors

Ксения Алексеевна Вютрих St Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation
Лилия Владимировна Куколь St Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation
Владимир Вилорович Лазик Vvedenskaya hospital, 4, Lazaretny per., St. Petersburg, 191180, Russian Federation

DOI:

https://doi.org/10.21638/11701/spbu11.2017.102

Abstract

The article provides an overview of published data on the state of the problem of combined chronic obstructive pulmonary disease and metabolic syndrome and the results of epidemiological studies on the combination of these nosological forms. The possible pathophysiological mechanisms of mutual worsening of these diseases are discussed. This review emphasizes the role of systemic inflammation, smoking, including passive smoking, as the leading risk factor. It also highlights the importance of determining the phenotype of chronic obstructive pulmonary disease to select the tactics for these patients. The value of adding obstructive sleep apnea syndrome was also considered. The indicated pathogenetic mechanisms that influence components of metabolic syndrome, including type 2 diabetes, on pulmonary function were considered. The article highlights the features of treatment, longterm trends in therapy of these diseases. Refs 46.

Keywords:

chronic obstructive pulmonary disease, phenotypes of chronic obstructive pulmonary disease, metabolic syndrome, type 2 diabetes mellitus, obstructive sleep apnea syndrome, systemic inflammation, smoking

Downloads

Download data is not yet available.

References

Литература

Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2014 г.) / пер. с англ. под ред. А. С. Белевского. М.: Российское респираторное общество, 2015. 93 с.

Fabbri L. M., Rabe K. F. From COPD to chronic systemic inflammatory syndrome? // Lancet. 2007.Vol. 370. P. 797–799.

Barnes P. J. Chronic obstructive pulmonary disease: Effects beyond the lungs // PLoS Med. 2010. N 7. P. 220–223.

Tkacova R. Systemic inflammation in chronic obstructive pulmonary disease: May adipose tissue play a role? Review of the literature and future perspectives // Mediators Inflamm. 2010. N 58. P. 59–65.

Рязанов А. С., Киреев С. А., Еременко Н. Н. Особенности клинического течения ХОБЛ при метаболическом синдроме: роль системного воспаления // Ожирение и метаболизм. 2010. Т. 2. С. 49–51.

Короли H. А., Ребров А. П. Некоторые механизмы развития легочной гипертонии у больных хроническими обструктивными заболеваниями легких // Терапевтический архив. 2005. № 3. С. 87–93.

Mannino D. M., Buist A. S. Global burden of COPD: risk factors, prevalence, and future trends // Lancet. 2007. Vol. 370 (9589). Р. 765–773.

Борисова Е. П. Ассоциация метаболического синдрома с хроническим бронхитом и хронической обструктивной болезнью легких у коренного населения Якутии: дис. … канд. мед. наук. Якутск, 2014. 159 с.

Борисова Е. П., Кылбанова Е. С. Клинико-функциональные особенности хронической обструктивной болезни легких у лиц якутской национальности с метаболическим синдромом // Медицинские науки. 2014. № 7. С. 241–245.

Мамедов М. Н. Руководство по диагностике и лечению метаболического синдрома. М.: Медицина, 2004. 72 с.

Киреев С. А., Рязанов А. С., Еременко Н. Н., Деменко Е. Г. ХОБЛ в сочетании с метаболическим синдромом: особенности клинических проявлений и лабораторные показатели системного воспаления // Биомедицина. 2010. № 4. С. 40–45.

Киреев С. А. Особенности клинического течения, параметров системного воспаления и перекисного окисления липидов у пациентов с ХОБЛ с метаболическим синдромом в зависимости от индекса массы тела: автореф. дис. … канд. мед. наук. М., 2011. 25 с.

Bateman E. D., Jardim J., Goehring U.-M., Brose M., Calverley P. Effect of roflumilast on hospitalizations in COPD patients: a post-hoc analysis // European Respiratory J. 2012. Vol. 40. P. 2109.

Caughey G. E., Preiss A. K., Vitry A. I., Gilbert A. L., Roughead E. E. Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications // Diabetes Care. 2013. Vol. 36, N 10. Р. 3009–3014.

Eisner M. D., Blanc P. D., Sidney S., Yelin E. H., Lathon P. V., Katz P. P., Tolstykh I., Ackerson L., Iribarren C. Body composition and functional limitation in COPD // Respir. Res. 2007. Vol. 8, N 1. Р. 7–15.

Mahishale V., Mahishale A., Patil B., Sindhuri A., Eti A. Screening for diabetes mellitus in patients with chronic obstructive pulmonary disease in tertiary care hospital in India // Nigerian Med. J. 2015.

Vol. 56, N 2. Р. 122–125.

Mekov E., Slavova Y., Tsakova A., Genova M., Kostadinov D., Minchev D., Marinova D. Metabolic syndrome in hospitalized patients with chronic obstructive pulmonary disease // Peer J. 2015. Vol. 2, N 3. Р. 1068.

Marquis K., Maltais F., Duguay V., Bezeau A. M., LeBlanc P., Jobin J., Poirier P. The metabolic syndrome in patients with chronic obstructive pulmonary disease // J. of Cardiopulmonary Rehabilitation. 2005. Vol. 25, N 4. Р. 226–232.

Filleu G. F., Beckwitt H. J., Reeves J. T., Mitchell R. S. Oxygen transport in two clinical types // Am. J.Med. 1968. Vol. 44. P. 26–28.

Абросимов В. Н. Хроническая обструктивная болезнь легких и пневмофиброз — еще один фенотип // Пульмонология. 2012. № 4. С. 95–99.

Guerra S., Sherrill D. L., Bobadilla A., Martinez F. D., Barbee R. A. The relation of body mass index to asthma, chronic bronchitis, and emphysema // Chest. 2002. Vol. 122, N 4. Р. 1256–1263.

Hersh C. P., Make B. J., Lynch D. A., Barr R. G., Bowler R. P., Calverley P. M., Castaldi P. J., Cho M. H., Coxson H. O., DeMeo D. L., Foreman M. G., Han M. K., Harshfield B. J., Hokanson J. E., Lutz S., Ramsdell

J. W., Regan E. A., Rennard S. I., Schroeder J. D., Sciurba F. C., Steiner R. M., Tal-Singer R., van Beek E. Jr.,Silverman E. K., Crapo J. D. Non-emphysematous chronic obstructive pulmonary disease is associated with

diabetes mellitus // BMC Pulm Med. 2014. Vol. 24, N 14. Р. 164.

Vestbo J., Anderson W., Coxson H. O., Crim C., Dawber F., Edwards L., Hagan G., Knobil K., Lomas D. A., MacNee W., Silverman E. K., Tal-Singer R. Evaluation of COPD Longitudinally to Identify Predictive Surrogate end-points (ECLIPSE) // Eur. Respir. J. 2008. Vol. 31, N 4. Р. 869–873.

Furutate R., Ishii T., Wakabayashi R., Motegi T., Yamada K., Gemma A., Kida K. Excessive visceral fat accumulation in advanced chronic obstructive pulmonary disease // Int. J. Chron. Obstruct. Pulmon. Dis. 2011. Vol. 6. P. 423–430.

Чучалин А. Г. Хроническая обструктивная болезнь легких и сопутствующие заболевания. Часть 2. ХОБЛ и некардиальные поражения // РМЖ. 2008. № 5. С. 246.

Schols A. M., Broekhuizen R., Weling-Scheepers C. A., Wouters E. F. Body composition and mortality in chronic obstructive pulmonary disease // Am. J. Clin. Nutr. 2005. Vol. 82, N 1. P. 53–59.

Травина Э. В., Хренов А. А. Характеристика тяжести течения ХОЗЛ у больных с метаболическим синдромом с использованием шкалы BODE // Крымский терапевтический журнал. 2009. № 1.С. 34–37.

Горелов А. И., Кучеренко Н. Г., Чижова О. Ю., Хильченко С. Г., Черных Е. И., Семенова Е. А., Рудакова С. М., Осипова М. Б., Бертова О. Н. Дыхательная недостаточность у больных хронической обструктивной болезнью легких в сочетании с синдромом обструктивного апноэ сна. Клиника, диагностика, дифференциальный подход к лечению // Вестник С.-Петерб. ун-та. Серия 11. Медицина. 2008. Вып. 1. С. 13–17.

Aurora R. N., Punjabi N. M. Obstructive sleep apnoea and type 2 diabetes mellitus: a bidirectional association // Lancet Respir. Med. 2013. Vol. 1, N 4. Р. 329–338.

Bertoletti L., Quenet S., Mismetti P. Clinical presentation and outcome of venous thromboembolism in COPD // Eur. Respir. J. 2012. Vol. 39. P. 862–868.

Bakker H., Jaddoe V. W. Cardiovascular and metabolic influences of fetal smoke exposure // Eur. J. Epidemiol. 2011. Vol. 26. P. 763–770.

Eze I. C., Schaffner E., Zemp E., von Eckardstein A., Turk A., Bettschart R., Schindler C., Probst-Hensch N. Environmental tobacco smoke exposure and diabetes in adult never-smokers // Environ. Health.2014. Vol. 25, N 13. Р. 74.

Sun S., Ji Y., Kersten S., Qi L. Mechanisms of inflammatory responses in obese adipose tissue // Annual Review of Nutrition. 2012. Vol. 32, N 1. Р. 261–286.

Филатова Ю. И., Перфильева М. В., Чернов А. В. Особенности клиники и терапии хронической обструктивной болезни легких на фоне метаболического синдрома // Молодой ученый. 2014.№ 7. С. 220–222.

Ступницкая А. Я. Оксидантно-антиоксидантный статус больных хронической обструктивной болезни легких, сочетающейся с метаболическим синдромом // Современная медицина: актуальные вопросы: сборник статей по материалам XXIII международной научно-практической конференции. Новосибирск, 2013. C. 37–45.

Sandler M. Is the lung a “target organ” in diabetes mellitus? // Arch. Intern. Med. 1990. Vol. 150.P. 1385–1388.

Ford E. S., Giles W. H., Mokdad A. H. Increasing prevalence of the metabolic syndrome among U.S. adults // Diabetes Care. 2004. Vol. 27, N 10. P. 2444–2449.

Kwon C. H., Rhee E. J., Song J. U., Kim J.-T., Kwag H. J., Sung K.-Ch. Reduced lung function is independently associated with increased risk of type 2 diabetes in Korean men // Cardiovasc. Diabetol. 2012. Vol. 11, N 38.

Kinney G. L., Black-Shinn J. L., Wan E. S., Make B., Regan E., Lutz S., Soler X., Silverman E. K., Crapo J., Hokanson J. E. Pulmonary function reduction in diabetes with and without chronic obstructive pulmonary disease // Diabetes Care. 2014. Vol. 37, N 2. Р. 389–395.

Agarwal A. S., Fuladi A. B., Mishra G., Tayade B. O. Spirometry and diffusion studies in patients with type-2 diabetes mellitus and their association with microvascular complications // Indian J. Chest. Dis. Allied Sci. 2010. Vol. 52, N 4. Р. 213–216.

Habib G., Dar-Esaif Y., Bishara H., Artul S., Badarny S., Chernin M., Jabbour A. The impact of corticosteroid treatment on hemoglobin A1C levels among patients with type-2 diabetes with chronic obstructive pulmonary disease exacerbation // Respir. Med. 2014. Vol. 108, N 11. Р. 1641–1646.

Ромашов Б. Б., Полякова Н. В. Особенности патогенеза, клиники и лечения сочетания хронической обструктивной болезни легких и сахарного диабета // Молодой ученый. 2015. № 13. С. 310–314.

Budweiser S., Harlacher M., Pfeifer M., Jörres R. A. Co-morbidities and hyperinflation are independent risk factors of all-cause mortality in very severe COPD // COPD. 2014. Vol. 11, N 4. Р. 388–400.

Lee C. T., Mao I. C., Lin C. H., Lin S. H., Hsieh M. C. Chronic obstructive pulmonary disease: a risk factor for type 2 diabetes: a nationwide population-based study // Eur. J. Clin. Invest. 2013. Vol. 43, N 11. Р. 1113–1119.

Верткин А. Л., Скотников А. С., Тихоновская Е. Ю., Оралбекова Ж. М., Губжокова О. М. Коморбидность при ХОБЛ: роль хронического системного воспаления // РМЖ. 2014. № 11. С. 811–816.

Shen T. C., Chung W. S., Lin C. L., Wei C. C., Chen C. H., Chen H. J., Tu C. Y., Hsia T. C., Shih C. M., Hsu W. H., Chung C. J. Does chronic obstructive pulmonary disease with or without type 2 diabetes mellitus influence the risk of lung cancer? Result from a population-based cohort study // PLoS One. 2014. Vol. 22. N 9 (5).

References

Global’naia strategiia diagnostiki, lecheniia i profilaktiki khronicheskoi obstruktivnoi bolezni legkikh (peresmotr 2014 g.) [Global strategy for the diagnosis, treatment and prevention of chronic obstructive pulmonary disease (revision 2014)]. Ed. by A. S. Belevsky. Moscow, Russian Respiratory Society, 2015. 93 p. (In Russian)

Fabbri L. M., Rabe K. F. From COPD to chronic systemic inflammatory syndrome? Lancet, 2007, vol. 370, pp. 797–799.

Barnes P. J. Chronic obstructive pulmonary disease: Effects beyond the lungs. PLoS Med, 2010, no. 7,pp. 220–223.

Tkacova R. Systemic inflammation in chronic obstructive pulmonary disease: May adipose tissue play a role? Review of the literature and future perspectives. Mediators Inflamm., 2010, no. 58, pp. 59–65.

Riazanov A. S., Kireev S. A., Eremenko N. N. Osobennosti klinicheskogo techeniia KhOBL pri metabolicheskom sindrome: rol’ sistemnogo vospaleniia [The clinical course of COPD in the metabolic syndrome: the role of systemic inflammation]. Ozhirenie i metabolizm [Obesity and Metabolism], 2010, no. 2,pp. 49–51. (In Russian)

Koroli H. A., Rebrov A. P. Nekotorye mekhanizmy razvitiia legochnoi gipertonii u bol’nykh

khronicheskimi obstruktivnymi zabolevaniiami legkikh [Some of the mechanisms of pulmonary hypertension in patients with chronic obstructive pulmonary disease]. Terapevticheskii arkhiv [Therapeutic archive], 2005, no. 3, pp. 87–93. (In Russian)

Mannino D. M., Buist A. S. Global burden of COPD: risk factors, prevalence, and future trends. Lancet,2007, vol. 370 (9589), pp. 765–773.

Borisova E. P. Assotsiatsiia metabolicheskogo sindroma s khronicheskim bronkhitom i khronicheskoi obstruktivnoi bolezn’iu legkikh u korennogo naseleniia Iakutii. Dis. … kand. med. nauk [Association of metabolic syndrome with chronic bronchitis and chronic obstructive pulmonary disease in the indigenous population of Yakutia. PhD. diss. of medicine sсience]. Yakutsk, 2014, p. 159. (In Russian)

Borisova E. P., Kylbanova E. S. Kliniko-funktsional’nye osobennosti khronicheskoi obstruktivnoi bolezni legkikh u lits iakutskoi natsional’nosti s metabolicheskim sindromom [Clinical and functional features

of chronic obstructive pulmonary disease in patients Yakut nationality with metabolic syndrome]. Meditsinskie nauki [Medical sciences], 2014, no. 7, pp. 241–245. (In Russian)

Mamedov M. N. Rukovodstvo po diagnostike i lecheniiu metabolicheskogo sindroma [Guidelines for the diagnosis and treatment of the metabolic syndrome]. Moscow, Medicine Publ., 2004, 72 p. (In Russian

Kireev S. A., Riazanov A. S., Eremenko N. N., Demenko E. G. KhOBL v sochetanii s metabolicheskim sindromom: osobennosti klinicheskikh proiavlenii i laboratornye pokazateli sistemnogo vospaleniia [COPD combined with the metabolic syndrome: clinical manifestations and laboratory indicators of systemic inflammation]. Biomeditsina [Biomedical], 2010, no. 4, pp. 40–45. (In Russian)

Kireev S. A. Osobennosti klinicheskogo techeniia, parametrov sistemnogo vospaleniia i perekisnogo okisleniia lipidov u patsientov s KhOBL s metabolicheskim sindromom v zavisimosti ot indeksa massy tela.Authoref. dis. … kand. med. nauk [The clinical course, the parameters of systemic inflammation and lipid peroxidation in patients with COPD with metabolic syndrome according to body mass index. Thesis of PhD].Moscow, 2011, 25 p. (In Russian)

Bateman E. D., Jardim J., Goehring U.-M., Brose M., Calverley P. Effect of roflumilast on hospitalizations in COPD patients: a post-hoc analysis. European Respiratory J., 2012, vol. 40, р. 2109.

Caughey G. E., Preiss A. K., Vitry A. I., Gilbert A. L., Roughead E. E. Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications. Diabetes Care, 2013, vol. 36, no. 10,pp. 3009–3014.

Eisner M. D., Blanc P. D., Sidney S., Yelin E. H., Lathon P. V., Katz P. P., Tolstykh I., Ackerson L., Iribarren C. Body composition and functional limitation in COPD. Respir. Res., 2007, vol. 8, no. 1, pp. 7–15.

Mahishale V., Mahishale A., Patil B., Sindhuri A., Eti A. Screening for diabetes mellitus in patients

with chronic obstructive pulmonary disease in tertiary care hospital in India. Nigerian Med. J., 2015, vol. 56,no. 2, pp. 122–125.

Mekov E., Slavova Y., Tsakova A., Genova M., Kostadinov D., Minchev D., Marinova D. Metabolic

syndrome in hospitalized patients with chronic obstructive pulmonary disease. Peer J., 2015, vol. 2, no. 3,p. 1068.

Marquis K., Maltais F., Duguay V., Bezeau A. M., LeBlanc P., Jobin J., Poirier P. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J. of Cardiopulmonary Rehabilitation , 2005,vol. 25, no. 4, pp. 226–232.

Filleu G. F., Beckwitt H. J., Reeves J. T., Mitchell R. S. Oxygen transport in two clinical types. Am. J.Med., 1968, vol. 44, pp. 26–28.

Abrosimov V. N. Khronicheskaia obstruktivnaia bolezn’ legkikh i pnevmofibroz — eshche odin fenotip [Chronic obstructive pulmonary disease and pulmonary fibrosis — another phenotype]. Pul’monologiia [Pulmonology], 2012, no. 4, pp. 95–99. (In Russian)

Guerra S., Sherrill D. L., Bobadilla A., Martinez F. D., Barbee R. A. The relation of body mass index to asthma, chronic bronchitis, and emphysema. Chest, 2002, vol. 122, no. 4, pp. 1256–1263.

Hersh C. P., Make B. J., Lynch D. A., Barr R. G., Bowler R. P., Calverley P. M., Castaldi P. J., Cho M. H.,Coxson H. O., DeMeo D. L., Foreman M. G., Han M. K., Harshfield B. J., Hokanson J. E., Lutz S., Ramsdell J. W., Regan E. A., Rennard S. I., Schroeder J. D., Sciurba F. C., Steiner R. M., Tal-Singer R., van Beek E. Jr., Silverman E. K., Crapo J. D. Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. BMC Pulm Med., 2014, vol. 24, no. 14, pp. 164.

Vestbo J., Anderson W., Coxson H. O., Crim C., Dawber F., Edwards L., Hagan G., Knobil K., Lomas

D. A., MacNee W., Silverman E. K., Tal-Singer R. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur. Respir. J., 2008, vol. 31, no. 4, pp. 869–873.

Furutate R., Ishii T., Wakabayashi R., Motegi T., Yamada K., Gemma A., Kida K. Excessive visceral

fat accumulation in advanced chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis., 2011, vol. 6, pp. 423–430.

Chuchalin A. G. Khronicheskaia obstruktivnaia bolezn’ legkikh i soputstvuiushchie zabolevaniia.

Chast’ 2. KhOBL i nekardial’nye porazheniia [Chronic obstructive pulmonary disease and related diseases.Part 2. COPD and non-cardiac lesions]. RMJ, 2008, no. 5. (In Russian)

Schols A. M., Broekhuizen R., Weling-Scheepers C. A., Wouters E. F. Body composition and mortality in chronic obstructive pulmonary disease. Am. J. Clin. Nutr., 2005, vol. 82, no.1, pp. 53–59.

Travina E. V., Hrenov A. A. Kharakteristika tiazhesti techeniia KhOZL u bol’nykh s metabolicheskim sindromom s ispol’zovaniem shkaly BODE [Characteristics of the severity of COPD in patients with metabolic syndrome using a scale BODE]. Krymskii terapevticheskii zhurnal [Crimean therapeutic magazine], 2009, no. 1, pp. 34–37. (In Russian)

Gorelov A. I., Kucherenko N. G., Chizhova O. Iu., Khil’chenko S. G., Chernykh E. I., Semenova E. A.,Rudakova S. M., Osipova M. B., Bertova O. N. Dykhatel’naia nedostatochnost’ u bol’nykh khronicheskoi

obstruktivnoi bolezn’iu legkikh v sochetanii s sindromom obstruktivnogo apnoe sna. Klinika, diagnostika, differentsial’nyi podkhod k lecheniiu [Respiratory failure in patients with chronic obstructive pulmonary disease combined with obstructive sleep apnea syndrome. The clinic, diagnosis, differential approach to treatment]. Vestnik of Saint Petersburg University. Series 11. Medicine, 2008, issue 1, pp. 13–17.

(In Russian)

Aurora R. N., Punjabi N. M. Obstructive sleep apnoea and type 2 diabetes mellitus: a bidirectional association. Lancet Respir. Med., 2013, vol. 1, no.4, pp. 329–338.

Bertoletti L., Quenet S., Mismetti P. Clinical presentation and outcome of venous thromboembolism in COPD. Eur. Respir. J., 2012, vol. 39, pp. 862–868.

Bakker H., Jaddoe V. W. Cardiovascular and metabolic influences of fetal smoke exposure. Eur. J. Epidemiol., 2011, vol. 26, pp. 763–770.

Eze I. C., Schaffner E., Zemp E., von Eckardstein A., Turk A., Bettschart R., Schindler C., Probst-

Hensch N. Environmental tobacco smoke exposure and diabetes in adult never-smokers. Environ. Health, 2014, vol. 25, no. 13, p. 74.

Sun S., Ji Y., Kersten S., Qi L. Mechanisms of inflammatory responses in obese adipose tissue. Annual Review of Nutrition, 2012, vol. 32, no. 1, pp. 261–286.

Filatova Iu. I., Perfil’eva M. V., Chernov A. V. Osobennosti kliniki i terapii khronicheskoi obstruktivnoi bolezni legkikh na fone metabolicheskogo sindroma [Features of clinic and therapy of chronic

obstructive pulmonary disease and metabolic syndrome]. Molodoi uchenyi [Young scientist], 2014, no. 7, pp. 220–222. (In Russian)

Stupnitskaia A. Ia. Oksidantno-antioksidantnyi status bol’nykh khronicheskoi obstruktivnoi bolezni legkikh, sochetaiushcheisia s metabolicheskim sindromom [Oxidant-antioxidant status in patients with chronic obstructive pulmonary disease, coupled with the metabolic syndrome].Sovremennaia meditsina: aktual’nye voprosy: sbornik statei po materialam XXIII mezhdunarodnoi nauchno-prakticheskoi konferentsii [Modern medicine: topical issues: a collection of articles on proceedings of the XXIII international scientificpractical conference]. Novosibirsk, 2013. (In Russian)

Sandler M. Is the lung a “target organ” in diabetes mellitus? Arch. Intern. Med., 1990, vol. 150, pp. 1385–1388.

Ford E. S., Giles W. H., Mokdad A. H. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care, 2004, vol. 27, no. 10, pp. 2444–2449.

Kwon C. H., Rhee E. J., Song J. U., Kim J.-T., Kwag H. J., Sung K.-Ch. Reduced lung function is independently associated with increased risk of type 2 diabetes in Korean men. Cardiovasc. Diabetol., 2012,vol. 11, no. 38.

Kinney G. L., Black-Shinn J. L., Wan E. S., Make B., Regan E., Lutz S., Soler X., Silverman E. K.,

Crapo J., Hokanson J. E. Pulmonary function reduction in diabetes with and without chronic obstructive

pulmonary disease. Diabetes Care, 2014, vol. 37, no. 2, pp. 389–395.

Agarwal A. S., Fuladi A. B., Mishra G., Tayade B. O. Spirometry and diffusion studies in patients with type-2 diabetes mellitus and their association with microvascular complications. Indian J. Chest. Dis. Allied Sci., 2010, vol. 52, no. 4, pp. 213–216.

Habib G., Dar-Esaif Y., Bishara H., Artul S., Badarny S., Chernin M., Jabbour A. The impact of corticosteroid treatment on hemoglobin A1C levels among patients with type-2 diabetes with chronic obstructive

pulmonary disease exacerbation. Respir. Med., 2014, vol. 108, no. 11, pp. 1641–1646.

Romashov B. B., Poliakova N. V. Osobennosti patogeneza, kliniki i lecheniia sochetaniia khronicheskoi obstruktivnoi bolezni legkikh i sakharnogo diabeta [Pathogenesis, clinic and treatment of a combination of chronic obstructive pulmonary disease and diabetes]. Molodoi uchenyi [Young scientist], 2015, no. 13,pp. 310–314. (In Russian)

Budweiser S., Harlacher M., Pfeifer M., Jörres R. A. Co-morbidities and hyperinflation are independent risk factors of all-cause mortality in very severe COPD. COPD, 2014, vol. 11, no. 4, pp. 388–400.

Lee C. T., Mao I. C., Lin C. H., Lin S. H., Hsieh M. C. Chronic obstructive pulmonary disease: a risk

factor for type 2 diabetes: a nationwide population-based study. Eur. J. Clin. Invest., 2013, vol. 43, no. 11, pp. 1113–1119.

Vertkin A. L., Skotnikov A. S., Tikhonovskaia E. Iu., Oralbekova Zh. M., Gubzhokova O. M. Komorbidnost’ pri KhOBL: rol’ khronicheskogo sistemnogo vospaleniia [Comorbidity in COPD: the role of chronic systemic inflammation]. RMJ, 2014, no. 11, pp. 811–816. (In Russian)

Shen T. C., Chung W. S., Lin C. L., Wei C. C., Chen C. H., Chen H. J., Tu C. Y., Hsia T. C., Shih C. M., Hsu W. H., Chung C. J. Does chronic obstructive pulmonary disease with or without type 2 diabetes mellitus

influence the risk of lung cancer? Result from a population-based cohort study. PLoS One, 2014, vol. 22,no. 9 (5).